Histomorphological changes after renal X-ray arteriography using iodine and gadolinium contrast media in an ischemic porcine model

Elmståhl, Barbara; Leander, Peter; Grant, Derek; Doughty, Richard William; Chai, Chun-Ming; Björk, Jonas; Almén, Torsten; Nyman, Ulf

doi:10.1080/02841850701663442

Cited by 14 publications

(11 citation statements)

References 46 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, The impact of iodixanol also persisted longer than the other agent. The result is similar to the detection of Elmstahl et al ( 2007 ). The detection might also indicate that the increased quality enhancement observed with iodixanol injection might provide improved images diagnosis and detailed descriptions of several organic disease.…”

Section: Discussionsupporting

confidence: 90%

Safety enhancement in adult body computed tomography scanning: comparison of iodixanol versus iohexol

Xiao

Zeng

et al. 2016

SpringerPlus

View full text Add to dashboard Cite

BackgroundThe aim of this study was to compare the safety and intra-individual contrast enhancement of low-osmolar monomeric iohexol and the iso-osmolar dimeric iodixanol in body computed tomography (CT) scanning.MethodsIn this single center, double-blind, prospective study, a total of 2000 consecutive patients undergoing adult body CT scanning were prospectively enrolled, with 1000 patients assigned to iodixanol and 1000 patients assigned to iohexol. In both groups, the contrast medium was injected at the rate of 3.5 ml/s. Subjective assessment of image quality for each image was determined using a 3-grading scale by three reviewers. Patients were monitored with questioning and vital signs before injection, immediately after injection, and at 24 and 48 h. Extensive laboratory evaluation also was performed.ResultsLaboratory results showed no significant difference across groups. There were also no detectable differences in image quality between the two contrast groups in this study. The total adverse reactions occurred in less than 1 % of individuals receiving iodixanol comparing to 2.5 % in iohexol group (P < 0.05). Among them, only 0.7 % patients injecting iodixanol suffered immediate events, comparing to 2 % patients in iohexol group. In all, 0.2 % patients with iodixanol and 0.5 % with iohexol had late allergic reaction. Further, No deaths occurred in any of the two groups.ConclusionsThe iso-osmolar iodixanol provides image quality compared with that of iohexol, with lower incidence of adverse events.

show abstract

Section: Discussionsupporting

confidence: 90%

Safety enhancement in adult body computed tomography scanning: comparison of iodixanol versus iohexol

Xiao

Zeng

et al. 2016

SpringerPlus

View full text Add to dashboard Cite

show abstract

“…It is unclear how much of a contribution to hyperintensity is due to gadolinium retained in the vasculature and how much is due to gadolinium that has entered the brain parenchyma. Gadolinium has been detected in the skin (a tissue known to retain high gadolinium for all GBCAs) of rats up to 364 days post dosing 25 . Our data show an initial rapid clearance up to 4 weeks, which diminishes thereafter.…”

Section: Discussionmentioning

confidence: 99%

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure

Davies¹,

Marino

Smith³

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Gadolinium based contrast agents (GBCA) are used to image patients using magnetic resonance (MR) imaging. In recent years, there has been controversy around gadolinium retention after GBCA administration. We sought to evaluate the potential toxicity of gadolinium in the rat brain up to 1-year after repeated gadodiamide dosing and tissue retention kinetics after a single administration. Histopathological and ultrastructural transmission electron microscopy (TEM) analysis revealed no findings in rats administered a cumulative dose of 12 mmol/kg. TEM-energy dispersive X-ray spectroscopy (TEM-EDS) localization of gadolinium in the deep cerebellar nuclei showed ~ 100 nm electron-dense foci in the basal lamina of the vasculature. Laser ablation-ICP-MS (LA-ICP-MS) showed diffuse gadolinium throughout the brain but concentrated in perivascular foci of the DCN and globus pallidus with no observable tissue injury or ultrastructural changes. A single dose of gadodiamide (0.6 mmol/kg) resulted in rapid cerebrospinal fluid (CSF) and blood clearance. Twenty-weeks post administration gadolinium concentrations in brain regions was reduced by 16–72-fold and in the kidney (210-fold), testes (194-fold) skin (44-fold), liver (42-fold), femur (6-fold) and lung (64-fold). Our findings suggest that gadolinium does not lead to histopathological or ultrastructural changes in the brain and demonstrate in detail the kinetics of a human equivalent dose over time in a pre-clinical model.

show abstract

“…In an experimental study, at the high dose of gadoversetamide ( (11). Furthermore, the same authors have also demonstrated that ICA (Iohexol) molecules were less nephrotoxic than the gadolinium chelates (gadopentetate and gadodiamid) in ischemic porcine kidneys (12).…”

Section: Discussionmentioning

confidence: 93%

Does the MRI or MRI contrast medium gadopentetate dimeglumine change the oxidant and antioxidant status in humans?

et al. 2013

View full text Add to dashboard Cite

show abstract

Histomorphological changes after renal X-ray arteriography using iodine and gadolinium contrast media in an ischemic porcine model

Cited by 14 publications

References 46 publications

Safety enhancement in adult body computed tomography scanning: comparison of iodixanol versus iohexol

Safety enhancement in adult body computed tomography scanning: comparison of iodixanol versus iohexol

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure

Does the MRI or MRI contrast medium gadopentetate dimeglumine change the oxidant and antioxidant status in humans?

Contact Info

Product

Resources

About